Vericiguat-ozhan

2.5 mg - 5 mg -10 mg

Film-Coated Tablet

Keep this leaflet. You may need to read it again

➢ **For further information, please contact**:
Phone: +98-21-88020579 or +98-21-40882675
Website: www.ozhanpharm.com
Email: info@ozhanpharm.com

Therapeutic Class:

Cardiac therapy, vasodilators used in cardiac diseases - stimulator of soluble guanylate cyclase (sGC)

Therapeutic Indication:

- vericiguat is used to treat adults with long term heart failure who recently have had an increase in heart failure symptoms. (In other words it is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy).

General Information for the patient:

This medicine has been prescribed specifically for the treatment of your current illness; therefore, Do not pass it on to others.
Talk to your physician or pharmacist if any of the following applies to you:

1. A history of allergy.
2. Pregnancy or breastfeeding.
3. If you have low blood pressure.

Contraindications:

Do not take vericiguat under the following conditions, and talk to your physician or pharmacist

- Allergic to vericiguat.
- If you are taking any medicine that contains another soluble guanylate cyclase stimulator, e.g. riociguat.
- Children and adolescents aged under 18 years because it has not been studied yet in this age group.
- If you have systolic blood pressure below 100 mmHg.
- If you have severe liver impairment.
- If you have severe kidney impairment (eGFR <15 mL/min/1.73 m^2) or on dialysis.

Pregnancy and Breastfeeding:

Pregnancy
Vericiguat should not be used during pregnancy, as it is not known if it harms the unborn baby. Talk to doctor about reliable forms of contraception. Must be used effective forms of birth control during treatment and for 1 month after stop treatment with vericiguat.
Breast-feeding
It is not known if vericiguat passes into breast milk and could harm baby. doctor will decide with you whether breast-feeding or Vericiguat therapy should be stopped.

Warnings:

Talk to your physician or pharmacist before taking vericiguat. Dose adjustment or temporary discontinuation of vericiguat may be necessary under the following conditions:
if you have**:**

- low blood pressure with symptoms like dizziness or light-headedness (systolic blood pressure below 100 mmHg) doctor may temporarily reduce vericuguat dose or interrupt your treatment with vericuguat.
- Severe kidney problems or are on dialysis.
- Severe liver problems.

Precautions:

Do not take this medicine with other medications without a doctor's prescription.

- This medicine may cause dizziness, if this happens, do not drive or use tools or machines.
- The potential for symptomatic hypotension, should be considered in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, history of hypotension, or concomitant treatment with antihypertensives (e.g. diuretics…) or organic nitrates.
- Take the missed tablet as soon as you remember on the same day of the missed dose. Do not take a double dose to make up for a forgotten tablet.

Drug Interactions:

Talk to your physician or pharmacist if you are taking any other medicines.

- Taking any medicine that contains another soluble guanylate cyclase stimulator, e.g. riociguat with vericiguat is contraindicated.
- The use of PDE5 inhibitors (e.g. sildenafil, tadalafil, vardenafil) is not recommended when taking vericiguat.
- The use of nitrates (e.g. isosorbide mononitrate, nitroglycerin) is not recommended when taking vericiguat.
- Vericiguat reduced systolic blood pressure by approximately 1 to 2 mmHg when co-administered with other medicinal products used in patients with heart failure.

❖ There was no interaction in the following cases, but caution is advised :

- Warfarin:

Administration of multiple doses of vericiguat (10 mg) once daily in healthy subjects did not alter the effect of a single dose of warfarin (25 mg) on prothrombin time and the activities of Factors II, VII, and X.

- Combination of sacubitril/valsartan:

Addition of multiple doses of vericiguat (2.5 mg) to multiple doses of sacubitril/valsartan (97/103 mg) in healthy subjects had no additional effect on seated blood pressure compared to administration of sacubitril/valsartan alone.

Dosage and Administration:

- Before starting vericiguat, care should be taken to optimise volume status and diuretic therapy to stabilize patients after the decompensation event, particularly in patients with very high NT-proBNP levels.
- The recommended starting dose is 1 tablet of 2.5 mg once daily. Increase the dose depending on how well the treatment is tolerated after about 2 weeks to 1 tablet of 5 mg once daily and after about another 2 weeks up to the maximum target dose of 1 tablet of 10 mg once daily.
- No dose adjustment is required for elderly patients.
- No dose adjustment is required in patients with estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73 m^2 (without dialysis). Treatment with vericiguat is not recommended in patients with eGFR <15 mL/min/1.73 m^2 at treatment initiation or on dialysis.
- No dose adjustment is required in patients with mild or moderate hepatic impairment. Treatment with vericiguat is not recommended in patients with severe hepatic impairment
- If patients experience tolerability issues (symptomatic hypotension or systolic blood pressure [SBP] less than 90 mmHg), temporary down-titration or discontinuation of vericiguat is recommended.
- Treatment should not be initiated in patients with SBP <100 mmHg.
- Take one tablet at the same time each day with food. If you cannot swallow the tablet, you may crush vericuguat and mix it with water. Take this mixture immediately.

Side Effects:

Like all medicines, this medicine can cause side effects, although not everybody gets them. if any of the side effects listed below become severe, tell your physician or pharmacist.

- **Very common:**
  - hypotension (low blood pressure)- orthostatic hypotension(dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position.
- **Common:**
  - Low number of red blood cells (anaemia), which can cause pale skin, weakness or breathlessness.
  - Dizziness
  - Headache
  - Symptomatic hypotension
  - Confusion
  - Nausea and vomiting
  - Indigestion (dyspepsia)
  - Heartburn (gastro-oesophageal reflux disease)
  - Sweating
  - Blurred vision
  - Unusual bleeding or bruising

Overdose:

In case of accidental overdose, immediately seek medical attention or contact a healthcare provider.

Storage Instructions:

- Store the medicine at temperatures below 30°C, away from light and moisture.
- Keep this medicine out of the sight and reach of children.

Packaging and Available Strengths:

➢ **2.5 mg film-coated tablets:**
Each film-coated tablet contains 2.5 mg vericiguat. 30 tablets per bottle in a cardboard box with a leaflet.
➢ **5 mg film-coated tablets**:
Each film-coated tablet contains 5 mg vericiguat. 14 tablets per bottle in a cardboard box with a leaflet.
➢ **10mg film-coated tablets**:
Each film-coated tablet contains 10 mg vericiguat. 30 tablets per bottle in a cardboard box with a leaflet.

References:

1. https://www.medicines.org.uk/emc(Medicines Compendium) (abpi)
2. BNF-85-2023
3. Uptodate 2025

Last Revised: 14 February 2026